NVL-330
Phase 1Small molecule
NVL-330 is one of 26 small molecule programs targeting Metastatic. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
25
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
27 competitors in Metastatic
#DrugCompanyPhaseTrials
1Opdivo
Bristol-Myers SquibbPhase 2
Keytruda
Merck & Co.Phase 2
Tecentriq
RochePhase 2
Trodelvy
GileadPhase 2
Padcev
PfizerPhase 2
Erbitux
IImclone
Phase 2
Jemperli
GGlaxo Dba Glaxosmithkline
Phase 2
Imbruvica
PPharmacyclics LLC.
Phase 2
Zejula
GGlaxo Dba Glaxosmithkline
Phase 2
JMKX001899
JJemincare
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NVL-330. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- NNuvalent Inc.